Insmed Incorporated
$143.43
▲
1.74%
2026-04-22 10:12:13
www.insmed.com
NMS: INSM
Explore Insmed Incorporated stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$31.02 B
Current Price
$143.43
52W High / Low
$212.75 / $63.81
Stock P/E
—
Book Value
$3.45
Dividend Yield
—
ROCE
-55.4%
ROE
-2.49%
Face Value
—
EPS
$-6.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1,664
Beta
1.1
Debt / Equity
101.43
Current Ratio
3.83
Quick Ratio
3.54
Forward P/E
211.7
Price / Sales
55.1
Enterprise Value
$32.69 B
EV / EBITDA
-33.34
EV / Revenue
53.91
Rating
Strong Buy
Target Price
$212.79
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aptevo Therapeutics Inc. | $5.21 | — | $6.24 M | — | -124.44% | -2.35% | $486 / $3.8 | $17.42 |
| 2. | OKYO Pharma Limited | $1.59 | — | $85.27 M | — | 127.79% | 82.36% | $3.35 / $1.11 | $-0.09 |
| 3. | ImmuCell Corporation | $8.02 | — | $72.74 M | — | 4.28% | -3.81% | $8.23 / $4.52 | $2.99 |
| 4. | Phio Pharmaceuticals Corp. | $1.27 | — | $14.75 M | — | -45.76% | -69.95% | $4.19 / $0.81 | $1.73 |
| 5. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
| 6. | Sol-Gel Technologies Ltd. | $70 | — | $228.83 M | — | -31.74% | -23.72% | $97.97 / $4.11 | $8.19 |
| 7. | Moleculin Biotech, Inc. | $2.56 | — | $13.66 M | — | -164.37% | -2.56% | $28.61 / $1.79 | $4.69 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 263.84 M | 142.34 M | 107.42 M | 92.82 M | 104.44 M |
| Operating Profit | -249.71 M | -261.35 M | -253.88 M | -229.84 M | -245.21 M |
| Net Profit | -328.49 M | -370.02 M | -321.69 M | -256.58 M | -235.55 M |
| EPS in Rs | -1.52 | -1.71 | -1.49 | -1.19 | -1.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 606.42 M | 363.71 M | 305.21 M | 245.36 M |
| Operating Profit | -994.78 M | -786.57 M | -680.93 M | -478.12 M |
| Net Profit | -1.28 B | -913.77 M | -749.57 M | -481.53 M |
| EPS in Rs | -5.92 | -4.23 | -3.47 | -2.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.26 B | 2.03 B | 1.33 B | 1.66 B |
| Total Liabilities | 1.53 B | 1.74 B | 1.66 B | 1.57 B |
| Equity | 738.98 M | 285.38 M | -331.92 M | 87.95 M |
| Current Assets | 1.79 B | 1.62 B | 929.06 M | 1.27 B |
| Current Liabilities | 468.87 M | 297.53 M | 225.63 M | 190.24 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -935.01 M | -683.88 M | -536.25 M | -400.44 M |
| Investing CF | -64.58 M | -583.17 M | -223.6 M | -34.58 M |
| Financing CF | 954.07 M | 1.34 B | 168.44 M | 793.27 M |
| Free CF | -967.58 M | -705.8 M | -549.53 M | -410.32 M |
| Capex | -32.56 M | -21.92 M | -13.29 M | -9.88 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 19.17% | 24.39% | — | — |
| Earnings Growth % | -21.91% | -55.66% | — | — |
| Profit Margin % | -251.24% | -245.59% | -196.26% | — |
| Operating Margin % | -216.26% | -223.1% | -194.87% | — |
| Gross Margin % | 76.43% | 78.52% | 77.53% | — |
| EBITDA Margin % | -225.12% | -216.3% | -182.33% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.